Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
Bioaffinity Technologies, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 13, 2026. The filing serves to announce the issuance of a press release containing financial information for the fiscal year ended December 31, 2025. The company is designated as an emerging growth company and trades on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants).
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the financial information for the year ended December 31, 2025, is included in a press release attached as Exhibit 99.1, which is not part of the text provided for analysis.
Material Changes
No material changes versus the prior comparable period can be identified from the source text. The filing acts as a notification of the release of annual results rather than a detailed financial statement itself.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, management commentary, risks, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 13, 2026) for actual revenue, net income, and cash flow figures for the year ended December 31, 2025.
- Verify the company's status as an emerging growth company and any associated accounting transition periods.
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on The Nasdaq Stock Market LLC.
- Check for any subsequent filings that may incorporate the financial data referenced in this 8-K.